FUDANZHANGJIANG<08231> - Results Announcement (Final, 2005, Summary)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced on 22/03/2006:
(stock code: 08231 )
Year end date :31/12/2005
Currency :RMB
Auditors' report :Unqualified
Important Note :
This result announcement form only contains extracted information from
and should be read in conjunction with the detailed results announcement
of the issuer, which can be viewed on the GEM website at
http://www.hkgem.com
(Audited) (Audited)
Current Last Corresponding
Period Period
from 01/01/2005 from 01/01/2004
to 31/12/2005 to 31/12/2004
RMB'000 RMB'000
Turnover : 20,117 10,567
Profit/(Loss) from Operations : (31,757) (24,446)
Finance cost : 0 0
Share of Profit/(Loss) of Associates : (2,900) (2,240)
Share of Profit/(Loss) of Jointly
Controlled Entites : N/A N/A
Profit/(Loss) after Taxation & MI : (29,085) (24,901)
% Change Over the Last Period : N/A
EPS / (LPS)
Basic (in dollar) : (RMB 0.041) (RMB 0.0351)
Diluted (in dollar) : N/A N/A
Extraordinary (ETD) Gain/(Loss) : 0 0
Profit (Loss) after ETD Items : (29,085) (24,901)
Final Dividends per Share : NIL NIL
(specify if with other options) : N/A N/A
B/C Dates for Final Dividends : N/A
Payable Date : N/A
B/C Dates for Annual General Meeting :17/05/2006 to 16/06/2006 bdi.
Other Distribution for Current Period : NIL
B/C Dates for Other Distribution : N/A
(bdi: both days inclusive)
For and on behalf of
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Signature :
Name : Wang Rui
Title : Company Secretary
Responsibility statement
The directors of the Company (the "Directors") as at the date hereof
hereby collectively and individually accept full responsibility for the
accuracy of the information contained in this results announcement form
(the "Information") and confirm, having made all reasonable inquiries,
that to the best of their knowledge and belief the Information are
accurate and complete in all material respects and not misleading and
that there are no other matters the omission of which would make the
Information herein inaccurate or misleading.The Directors acknowledge
that the Stock Exchange has no responsibility whatsoever with regard to
the Information and undertake to indemnify the Exchange against all
liability incurred and all losses suffered by the Exchange in connection
with or relating to the Information.
Remarks:
1. Basis of preparation
The consolidated financial statements of the Group have been
prepared in accordance with International Financial
Reporting Standards ("IFRS"). These financial statements
are prepared under the historical cost convention, except
that the available-for-sale investments are shown at fair
value.
The results are audited and have been reviewed by the Audit Committee.
2. Financial review
The Group's consolidated turnover for the year ended 31
December 2005 amounted to approximately RMB20,117,000,
compared to RMB10,567,000 for the same period in 2004. During
the year under review, approximately RMB9,500,000 (or 47% of
the total turnover) was derived from the income of technology
transfer, and the rest of approximately RMB10,617,000 (or 53%
of the total turnover) came from the sale of diagnostic
products and the provision of the ancillary services. In
contrast, approximately RMB4,200,000 (or 40% of the total
turnover) was derived from the income of technology transfer,
and the rest of approximately RMB6,367,000 (or 60% of the total
turnover) came from the sale of diagnostic products and the
provision of the ancillary services for the year 2004.
For the year ended 31 December 2005, cost of sales of the Group
was RMB12,093,000, while the corresponding figure for the same
period last year was RMB8,325,000. The increase in cost of
sales is lower than the increase in revenue, which indicates
that cost control of the Group has been healthier.
For the year ended 31 December 2005, operating loss of the
Group was RMB31,757,000, comparing to RMB24,446,000 for the
year 2004. Total expenses grew up by 39% from that of last
year as a result of the rising expenditure of research and
development costs, distribution costs, administrative and
other expenses, leading to a dropping operating result.
A loss attributable to shareholders of the company of RMB29,085,000 was
recorded for the year ended 31 December 2005, compared with
RMB24,901,000 for the same period in 2004.
3. Loss per share
The calculation of the loss per share for the year ended 31
December 2005 was based on the loss attributable to shareholders
of the company approximately RMB29,085,000
and the total shares of 710,000,000 as at 31 December 2005. The
calculation of the loss per share for the year ended 31 December
2004 was based on the loss attributable to shareholders of
the company of RMB24,901,000 and the total shares
of 710,000,000 as at 31 December 2004.
Diluted loss per share has not been calculated for the
year ended 31 December 2005 and year ended 31 December 2004
respectively as there was no dilutive potential ordinary share during
the years then ended.
|